 |
|
Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan SyndromeA Randomized Controlled Trial
Anna A. Ahimastos, PhD;
Anuradha Aggarwal, MD, PhD;
Kellie M. D’Orsa, DMU;
Melissa F. Formosa, BSc;
Anthony J. White, FRACP, PhD;
Ravi Savarirayan, FRACP, MD;
Anthony M. Dart, DPhil, FRCP;
Bronwyn A. Kingwell, PhD
JAMA. 2007;298:1539-1547.
Context Aortic stiffness is increased in Marfan syndrome contributing to aortic dilatation and rupture, the major cause of premature death in this population. Angiotensin-converting enzyme inhibitors have been shown to reduce arterial stiffness.
Objective To determine whether perindopril therapy reduces aortic stiffness and attenuates aortic dilatation in patients with Marfan syndrome.
Design, Setting, and Participants A randomized, double-blind, placebo-controlled trial of 17 patients with Marfan syndrome (mean [SD], 33 [6] years) taking standard  -blocker therapy, initiated in January 2004 and completed in September 2006, at Alfred Hospital Marfan Syndrome Clinic, Melbourne, Australia.
Intervention Patients were administered 8 mg/d of perindopril (n = 10) or placebo (n = 7) for 24 weeks.
Main Outcome Measures Indices of arterial stiffness were assessed via systemic arterial compliance, and central and peripheral pulse wave velocities. Aortic root diameters were assessed at 4 sites via transthoracic echocardiography.
Results Perindopril reduced arterial stiffness as indicated by increased systemic arterial compliance (mean [SEM], 0.33 [0.01] mL/mm Hg at baseline to 0.54 [0.04] mL/mm Hg at 24 weeks in perindopril group vs 0.30 [0.01] mL/mm Hg to 0.29 [0.01] mL/mm Hg in placebo group, P = .004), and reduced central (7.6 [0.4] m/s to 5.9 [0.3] m/s in perindopril group, P < .001 vs placebo) and peripheral (10.9 [0.4] m/s to 8.7 [0.4] m/s in perindopril group, P < .001 vs placebo) pulse wave velocities. In addition, perindopril significantly reduced aortic root diameters relative to placebo in both end-systole and end-diastole (P<.01 to P < .001 for all comparisons between groups). Although perindopril marginally reduced mean arterial pressure (from 81 [2] mm Hg to 80 [1] mm Hg in perindopril group vs 83 [2] mm Hg to 84 [3] mm Hg in placebo group, P = .004), the observed changes in both stiffness and left ventricular outflow tract diameter remained significant when mean arterial pressure was included as a covariate. Transforming growth factor (TGF-), which contributes to aortic degeneration in Marfan syndrome, was reduced by perindopril compared with placebo in both latent (59 [6] ng/mL to 45 [3] ng/mL in perindopril group, P = .01 vs placebo) and active (46 [2] ng/mL to 42 [1] ng/mL in perindopril group, P = .02 vs placebo) forms.
Conclusions Perindopril reduced both aortic stiffness and aortic root diameter in patients with Marfan syndrome taking standard -blocker therapy, possibly through attenuation of TGF- signaling. Large clinical trials are needed to assess the clinical benefit of angiotensin II blockade in Marfan syndrome.
Trial Registration clinicaltrials.gov Identifier: NCT00485368
Author Affiliations: Alfred and Baker Medical Unit, Baker Heart Research Institute (Drs Ahimastos, White, Dart, and Kingwell, and Mss D’Orsa and Formosa); Department of Cardiology, Royal Melbourne Hospital (Dr Aggarwal); and Murdoch Children's Research Institute and University of Melbourne (Dr Savarirayan), Melbourne, Australia.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on Research in Marfan Syndrome and Related Disorders
Pearson et al.
Circulation 2008;118:785-791.
FULL TEXT
Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome
Brooke et al.
NEJM 2008;358:2787-2795.
ABSTRACT
| FULL TEXT
The year in hypertension.
Williams
J Am Coll Cardiol 2008;51:1803-1817.
FULL TEXT
|
